Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Drug Reviews To Be Restructured As Office Shifts Away From Divisions Organized Around Molecule Size

Executive Summary

FDA's Office of Oncology Drug Products is undergoing a reorganization aimed at making its structure more similar to the rest of the review offices in the Center for Drug Evaluation and Research
Advertisement

Related Content

FDA Reorganization Advocates Seek Senate Boost For Disease-Oriented Structure
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
FDA Oncology Products Office Reorganization Keeps Leadership Intact
Drug Review Reorganization Boosts Advisory Role Of Medical Imaging Division
Drug Review Reorganization Boosts Advisory Role Of Medical Imaging Division
FDA's ONP Reorganization Challenges Industry To Prioritize OTCs
Office Of New Drugs Reorganization Should Better Balance Workload, FDA Says
No Drama Dendreon: Anticipated Provenge Launch Appears On Track
FDA Reorganization Plan Would Eliminate One ODE, Split Neuropharm Division
FDA Reorganization Plan Would Eliminate One ODE, Split Neuropharm Division

Topics

Advertisement
UsernamePublicRestriction

Register

PS052116

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel